|
Market Closed -
Nasdaq
00:00:00 07/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 39.42 USD | +1.60% |
|
-9.42% | -50.17% |
| 11-07 | Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing | RE |
| 11-02 | Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target | RE |
| Market Cap | 6.55B 5.88B 5.37B 4.9B 9.24B 616B 9.53B 64.72B 25.81B 329B 24.59B 24.06B 1,037B | P/E 2026 * |
-11.1x | P/E 2027 * | -20.2x |
|---|---|---|---|---|---|
| Enterprise Value | 6.45B 5.78B 5.29B 4.82B 9.09B 606B 9.38B 63.71B 25.4B 323B 24.2B 23.68B 1,021B | EV / Sales 2026 * |
6.99x | EV / Sales 2027 * | 4.87x |
| Free-Float |
99.06% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IONS | Delayed | |
CBOE
| IONS | Real-time | |
|
Tradegate
| ISI | Real-time | |
|
Mexican S.E.
| IONS * | End-of-day quote | |
|
Xetra
| ISI | Delayed | |
|
Boerse Muenchen
| ISI | Real-time | |
|
Deutsche Boerse AG
| ISI | Delayed | |
|
Börse Stuttgart
| ISI | Delayed | |
|
Borsa Italiana
| 1IONS | End-of-day quote |
Last Transcript: Ionis Pharmaceuticals, Inc.
| 1 day | +1.60% | ||
| 1 week | -9.42% | ||
| Current month | -9.42% | ||
| 1 month | -10.73% | ||
| 3 months | -30.30% | ||
| 6 months | -48.15% | ||
| Current year | -50.17% |
| 1 week | 38.3 |  | 43.91 |
| 1 month | 38.3 | | 45.84 |
| Current year | 38.3 | | 86.74 |
| 1 year | 38.3 | | 86.74 |
| 3 years | 23.95 | | 86.74 |
| 5 years | 23.95 | | 86.74 |
| 10 years | 23.95 | | 86.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/31/26 A | Others | Chief Technology Officer | 110 | 0.0001% | ||
| 8/31/26 A | Others | Executive/Senior Manager | 58 | 0.0000% | ||
| 8/31/26 A | Others | Founder | 98 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.60% | -9.42% | -46.40% | -17.38% | 6.55B | |
| -4.83% | +3.51% | +55.00% | +63.79% | 66.7B | |
| +0.02% | +1.07% | +11.72% | +75.63% | 56.88B | |
| -1.34% | +2.98% | +25.08% | +100.18% | 56.53B | |
| +5.09% | +9.89% | +27.19% | +105.85% | 46.49B | |
| +2.62% | +1.68% | +29.16% | +35.86% | 44.8B | |
| +8.24% | +0.51% | +215.16% | +794.74% | 41.59B | |
| -1.86% | +10.13% | +28.14% | +55.48% | 35.35B | |
| -2.97% | -9.84% | +90.91% | +73.49% | 33.29B | |
| +5.19% | +1.62% | -39.69% | +368.87% | 25.1B | |
| Average | +1.18% | +1.44% | +39.63% | +165.65% | 41.33B | |
| Weighted average by Cap. | +0.67% | +2.88% | +48.38% | +162.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 922M 827M 756M 690M 1.3B 86.71B 1.34B 9.11B 3.63B 46.26B 3.46B 3.39B 146B | 1.36B 1.22B 1.11B 1.02B 1.92B 128B 1.98B 13.44B 5.36B 68.21B 5.1B 4.99B 215B |
| Net income | -579M -520M -475M -434M -817M -54.46B -842M -5.72B -2.28B -29.06B -2.17B -2.13B -91.74B | -327M -294M -268M -245M -461M -30.77B -476M -3.23B -1.29B -16.42B -1.23B -1.2B -51.83B |
| Net Debt | -103M -92.37M -84.42M -77.06M -145M -9.68B -150M -1.02B -406M -5.17B -387M -378M -16.31B | 68.31M 61.27M 55.99M 51.11M 96.3M 6.42B 99.33M 675M 269M 3.43B 256M 251M 10.82B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/11/26 | $39.42 | +1.60% | 2,911,840 |
| 05/11/26 | $38.80 | -3.36% | 2,975,955 |
| 04/11/26 | $40.15 | -0.67% | 4,102,754 |
| 03/11/26 | $40.42 | -1.99% | 4,006,909 |
| 02/11/26 | $41.24 | -5.24% | 2,559,959 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IONS Stock
Select your edition
All financial news and data tailored to specific country editions
